Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs strong continued innovation in HIV, solid oncology launches, and smart future acquisitions to guarantee mid-single-digit growth over our 10-year forecast.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.66 | 45.47 | 12.20 |
Price/Book Value | 16.39 | 8.59 | 4.24 |
Price/Sales | 6.40 | 5.44 | 2.27 |
Price/Cash Flow | 12.89 | 16.34 | 9.70 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.75 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | −1.28 | 4.28 | 9.51 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | −0.75% | 6.27% | 11.66% |
Return on Equity (Normalized) | −2.11% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 0.26% | 9.82% | 22.63% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#blqm%Gd | LOCK|<kl | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|t!>Z&t | LOCK|T$ | $616B | |||
| AbbVie Inc
ABBV
| LOCK|sf?<xwx | LOCK|q% | $504B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|&!?@thB | LOCK|@QG | $366B | |||
| Merck & Co Inc
MRK
| LOCK|dKB?#f | LOCK|dm | $360B | |||
| Novartis AG ADR
NVS
| LOCK|<NmS&#@$ | LOCK|$@ | $286B | |||
| AstraZeneca PLC
AZN
| LOCK|f&RxL^< | LOCK|l%% | $256B | |||
| Amgen Inc
AMGN
| LOCK|Gmd<dP<s | LOCK|Z! | $234B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|^pTzGd | LOCK|VF | $172B |
United States